



[Oncofocus] Patient Test Report

| | | | |
|-----------------------|----------------------------------|-----------------------------|-----|
| Surname | | Requesting Clinician | |
| Forename DOB | | Date requested | |
| Gender | Female | Tumour % | 55% |
| Histology # | | Tumour % | n/a |
| Primary site | Lung | (macrodissected) | |
| Tumour subtype | Invasive Squamous Cell Carcinoma | | |
| Tissue Type | Lung Pancoast | | |

Comment:

The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus assay on which the sample was run met all assay specific quality metrics.

221 genes were targeted using 2530 unique amplicons covering oncogenes, fusion genes, genes susceptible to copy number variation and tumour suppressors. Actionable genetic variants detected by Oncofocus are linked to 466 anti-cancer targeted therapies.

The following actionable variants were detected:

Variant Summary

Sample Cancer Type: Non-Small Cell Lung Cancer

In this cancer type
 In other cancer type
 In this cancer type and other cancer types
 Contraindicated
 Both for use and contraindicated
 No evidence

| Gene Variant | EMA | US-FDA | ESMO | US-NCCN | Global Clinical Trials |
|--|-----|--------|------|---------|------------------------|
| PTEN p.(V166fs) c.497_513delTAACTATTCCCAGTCAG | ✗ | ✗ | ✗ | ✗ | ● (11) |
| TP53 p.(V157F) c.469G>T | ✗ | ✗ | ✗ | ✗ | ● (8) |
| FBXW7 p.(R441W) c.1321C>T | ✗ | ✗ | ✗ | ✗ | ● (2) |

EMA: European Medicine Agency, **US-FDA:** United States-Food and Drug Administration, **ESMO:** European Society for Medical Oncology, **US-NCCN:** United States-National Comprehensive Cancer Network. Numbers in parentheses indicate the number of relevant therapies with evidence. Hotspot variants with >10% alternate allele reads, and in >10 unique reads are classified as 'detected' with an assay sensitivity and positive predictive value (PPV) of 92%. Copy number variants; amplifications of CN> 6 with the 5% confidence value of ≥4 after normalization and deletions with 95% CI ≤1 are classified as present when the tumour% >50% with a sensitivity of 80% and PPV 100%. Gene Fusions are reported when occurring in >20 counts and meeting the thresholds of assay specific internal RNA quality control with a sensitivity of 92% and PPV of 99%. Supplementary technical information is available upon request.

ONC17-:

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Relevant Therapy Summary

In this cancer type
 In other cancer type
 In this cancer type and other cancer types
 Contraindicated
 Both for use and contraindicated
 No evidence

PTEN p.(V166fs) c.497_513delTA ACTATTCCCAGTCAG

| Relevant Therapy | EMA | US-FDA | ESMO | US-NCCN | Global Clinical Trials* |
|--|-----|--------|------|---------|-------------------------|
| everolimus | × | × | × | × | ● (II) |
| GSK-2636771 | × | × | × | × | ● (II) |
| olaparib + vistusertib | × | × | × | × | ● (II) |
| selumetinib + vistusertib | × | × | × | × | ● (I/II) |
| AZD-5363 | × | × | × | × | ● (I) |
| AZD-5363 + olaparib | × | × | × | × | ● (I) |
| AZD8186, AZD8186 + abiraterone acetate + prednisone, AZD8186 + vistusertib | × | × | × | × | ● (I) |
| LY-3023414, LY-3023414 + midazolam | × | × | × | × | ● (I) |
| MSC-2363318A | × | × | × | × | ● (I) |
| palbociclib + pictilisib, palbociclib + taselisib | × | × | × | × | ● (I) |
| PQR-309 | × | × | × | × | ● (I) |

TP53 p.(V157F) c.469G>T

| Relevant Therapy | EMA | US-FDA | ESMO | US-NCCN | Global Clinical Trials* |
|------------------------|-----|--------|------|---------|-------------------------|
| MK-1775 + olaparib | × | × | × | × | ● (II) |
| nintedanib | × | × | × | × | ● (II) |
| pazopanib | × | × | × | × | ● (II) |
| ixazomib + vorinostat | × | × | × | × | ● (I) |
| MK-1775 | × | × | × | × | ● (I) |
| pembrolizumab + p53MVA | × | × | × | × | ● (I) |

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available. See global clinical trials section in the pages to follow.

ONC17-:

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Relevant Therapy Summary (continued)

In this cancer type
 In other cancer type
 In this cancer type and other cancer types
 Contraindicated
 Both for use and contraindicated
 No evidence

TP53 p.(V157F) c.469G>T (continued)

| Relevant Therapy | EMA | US-FDA | ESMO | US-NCCN | Global Clinical Trials* |
|-------------------------------|-----|--------|------|---------|-------------------------|
| SGT-53, SGT-53 + chemotherapy | ✗ | ✗ | ✗ | ✗ | ● (I) |
| VX-970 + chemotherapy | ✗ | ✗ | ✗ | ✗ | ● (I) |

FBXW7 p.(R441W) c.1321C>T

| Relevant Therapy | EMA | US-FDA | ESMO | US-NCCN | Global Clinical Trials* |
|------------------|-----|--------|------|---------|-------------------------|
| palbociclib | ✗ | ✗ | ✗ | ✗ | ● (II) |
| prexasertib | ✗ | ✗ | ✗ | ✗ | ● (II) |

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available. See global clinical trials section in the pages to follow.

ONC17-:

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Current Global Clinical Trials Information

Global Clinical Trials information is current as of 2016-12-01. For the most up-to-date information regarding a particular trial, search www.clinicaltrials.gov by NCT ID or search local clinical trials authority website by local identifier listed in 'Other identifiers'.

PTEN p.(V166fs) c.497_513delTA ACTATTCCCAGTCAG

NCT02583542

A Phase Ib/Ia Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers.

Cancer type: Non-Small Cell Lung Cancer

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: 009896QM, EudraCT Number: 2014-002613-31, IRAS ID 172356, Torcmek, TrialTroveID-265019, UKCRN ID:18725

Population segments: EGFR, FGFR, HER2 negative, HER2 positive, KRAS, Second line or greater/Refractory/Relapsed, Squamous Cell, Stage III, Stage IV, Triple receptor negative

Phase: I/II

Therapy: selumetinib + vistusertib

Location: United Kingdom

NCT01655225

A Phase I First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer

Cancer type: Non-Small Cell Lung Cancer

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: 12-286, 13517, I6A-MC-CBBA, REFMAL 276, TrialTroveID-172222

Population segments: Estrogen receptor positive, Extranodal marginal zone B-cell lymphoma (MALT), First line, Follicular lymphoma (FL), HER2 negative, Indolent, Other subtype, Progesterone receptor positive, Second line or greater/Refractory/Relapsed, Small lymphocytic lymphoma (SLL), Squamous Cell, Stage III, Stage IV, Untreated, Waldenstrom's macroglobulinemia (WM)

Phase: I

Therapies: LY-3023414, LY-3023414 + midazolam

Locations: Italy, United States

US States: NY, OK, PA, TN

US Contact: Eli Lilly and Company [877-285-4559]

ONC17-:www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

PTEN p.(V166fs) c.497_513delTA ACTATTCCCAGTCAG (continued)**NCT02029001**

A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors MOST: My own specific treatment

Cancer type: Unspecified Solid Tumor

Variant class: PTEN mutation

Other identifiers: ET12-081, EudraCT number: 2012-004510-34, MOST, ProfiLER, TrialTroveID-200294

Population segments: Maintenance/Consolidation, Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Phase: II

Therapy: everolimus

Location: France

NCT02465060

Molecular Analysis for Therapy Choice (MATCH)

Cancer type: Unspecified Solid Tumor

Variant class: PTEN mutation

Other identifiers: 15-7002, CTSU/EAY131, EAY131, EAY131-A, EAY131-B, EAY131-E, EAY131-F, EAY131-G, EAY131-H, EAY131-I, EAY131-MATCH, EAY131-N, EAY131-P, EAY131-Q, EAY131-R, EAY131-S1, EAY131-S2, EAY131-T, EAY131-U, EAY131-V, EAY131-X, ECOGEAY131-M, MATCH, NCI-2015-00054, NCI-MATCH, TrialTroveID-258747

Population segments: (N/A), Aggressive, ALK, Classical, EGFR, HER2 positive, Indolent, Nodular lymphocyte-predominant, Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Other inclusion criteria: PTEN expression

Phase: II

Therapy: GSK-2636771

Location: United States

US States: AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WV, WY

US Contact: Multiple contacts: See www.clinicaltrials.gov for complete list of contacts.

ONC17-:www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

PTEN p.(V166fs) c.497_513delTA ACTATTCCCAGTCAG (continued)**NCT02576444**

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors

Cancer type: Unspecified Solid Tumor

Variant class: PTEN mutation

Other identifiers: 1508016363, OLAPCO, TrialTroveID-266161

Population segments: First line, Second line or greater/Refractory/Relapsed, Stage IV

Phase: II

Therapy: olaparib + vistusertib

Location: United States

US States: CT, MA

US Contact: Multiple contacts: See www.clinicaltrials.gov for complete list of contacts.

NCT01884285

A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB mutated/ amplified Advanced Solid Malignancies as Monotherapy and in Combination with Abiraterone Acetate or AZD2014

Cancer type: Unspecified Solid Tumor

Variant class: PTEN mutation

Other identifiers: 13-300, 20131275, D4620C00001, EudraCT Number: 2013-000703-17, IRAS ID: 129536, NCI-2013-02191, TrialTroveID-189056

Population segments: HER2 negative, Hormone refractory, Second line or greater/Refractory/Relapsed, Squamous Cell, Stage III, Stage IV, Triple receptor negative

Phase: I

Therapies: AZD8186, AZD8186 + abiraterone acetate + prednisone, AZD8186 + vistusertib

Locations: Canada, Spain, United Kingdom, United States

US States: MA, MI, WA, WI

US Contact: AstraZeneca Clinical Study Information Center [877-240-9479; information.center@astrazeneca.com]

ONC17-:www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

PTEN p.(V166fs) c.497_513delTAACTATTCCCAGTCAG (continued)**NCT01971515**

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Cancer type: Unspecified Solid Tumor

Variant class: PTEN aberration

Other identifiers: 2013-0525, CHRMS 14-081, EMR100018-001, NCI-2013-02370, TrialTroveID-196334

Population segments: Aggressive, Classical, EGFR, HER2 positive, Indolent, Nodular lymphocyte-predominant, Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Exclusion criteria variant classes: AKT2 amplification, AKT2 mutation

Phase: I

Therapy: MSC-2363318A

Location: United States

US States: AL, CA, FL, MI, NY, TX, VT

US Contact: US Medical Information [888-275-7376]

NCT01226316

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Cancer type: Unspecified Solid Tumor

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: 102084, 14-214, 14-430, 2014-0160, CR1322AZ, D3610C00001, EudraCT Number: 2010-022167-35, IRAS ID: 62131, JapicCTI-152844, M10AZD, NCI-2014-01803, NL33755.031.10, P1TGIVEN, TrialTroveID-136773

Population segments: Adenocarcinoma, Estrogen receptor positive, HER2 positive, Hormone refractory, Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Exclusion criteria variant classes: BRAF mutation, HRAS mutation, KRAS mutation, NRAS mutation

Phase: I

Therapy: AZD-5363

Locations: Canada, Denmark, France, Italy, Japan, Netherlands, Singapore, Spain, United States

US States: CA, CO, CT, NY, OK, PA, SC, TN, TX

US Contact: AstraZeneca Clinical Study Information [877-240-9479; information.center@astrazeneca.com]

ONC17-:www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

PTEN p.(V166fs) c.497_513delTA ACTATTCCCAGTCAG (continued)**NCT02338622**

A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours

Cancer type: Unspecified Solid Tumor

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: 14/LO/0103, CCR4058, ComPAKT, CRUKD/14/004, EudraCT number: 2013-004692-13, TrialTroveID-213474, UKCRN ID 16550

Population segments: HER2 negative, Hormone refractory, Second line or greater/Refractory/Relapsed, Stage III, Stage IV, Triple receptor negative

Phase: I

Therapy: AZD-5363 + olaparib

Location: United Kingdom

NCT02389842

PIPA: A Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination With Palbociclib, With the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers

Cancer type: Unspecified Solid Tumor

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: CCR4191, EudraCT Number: 2014-002658-37, IRAS ID 159997, PIPA, TrialTroveID-253778

Population segments: HER2 negative, Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Phase: I

Therapies: palbociclib + pictilisib, palbociclib + tasiselisib

Location: United Kingdom

NCT02483858

Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors.

Cancer type: Unspecified Solid Tumor

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: EudraCT Number: 2015-003919-38, I 258914, IRAS ID: 193390, PQR309-003, REec-2016-2264, TrialTroveID-260655

Population segments: Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Phase: I

Therapy: PQR-309

Location: United States

US State: NY

US Contact: Dr. Alex Adjei [Alex.Adjei@RoswellPark.org]

ONC17-:

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

TP53 p.(V157F) c.469G>T**NCT02299141**

A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Cancer type: Non-Small Cell Lung Cancer

Variant class: TP53 mutation

Other identifiers: 14-x346, 201412116, NCI-2014-02625, TrialTroveID-218546

Population segments: FGFR, First line, Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Phase: II

Therapy: nintedanib

Location: United States

US State: MO

US Contact: Dr. Ramaswamy Govindan [314-362-5654; rgovindan@wustl.edu]

NCT02193152

A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Cancer type: Non-Small Cell Lung Cancer

Variant class: TP53 mutation

Other identifiers: 14-X182, 201408009, 201566, NCI-2014-01760, PRMC 14-X182, TrialTroveID-213213

Population segments: First line, Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Phase: II

Therapy: pazopanib

Location: United States

US State: MO

US Contact: Dr. Daniel Morgensztern [314-362-5737; danielmorgensztern@wustl.edu]

NCT02432963

A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab

Cancer type: Non-Small Cell Lung Cancer

Variant class: TP53 mutation

Other identifiers: 116634, 122284, 122771, 124524, 15002, NCI-2015-00653, TrialTroveID-256830

Population segments: HER2 negative, Second line or greater/Refractory/Relapsed, Stage III, Stage IV, Triple receptor negative, Unresectable

Phase: I

Therapy: pembrolizumab + p53MVA

Location: United States

US State: CA

US Contact: Vincent Chung [800-826-4673]

ONC17-:www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

TP53 p.(V157F) c.469G>T (continued)**NCT02157792**

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

Cancer type: Non-Small Cell Lung Cancer

Variant class: TP53 mutation

Other identifiers: 112876, 14-040, EudraCT Number: 2012-003126-25, NCI-2014-02042, OSU-13211, TrialTroveID-190735, VICCBRE1587, VX12-970-001

Population segments: First line, HER2 negative, Second line or greater/Refractory/Relapsed, Stage III, Stage IV, Triple receptor negative

Phase: I

Therapy: VX-970 + chemotherapy

Locations: United Kingdom, United States

US States: CA, CO, GA, IL, MA, MI, MO, NY, OH, SC, TN, TX, VA, WA

US Contact: Medical Monitor [617-341-6777; medicalinfo@vrtx.com]

NCT02576444

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors

Cancer type: Unspecified Solid Tumor

Variant class: TP53 mutation

Other identifiers: 1508016363, OLAPCO, TrialTroveID-266161

Population segments: First line, Second line or greater/Refractory/Relapsed, Stage IV

Phase: II

Therapy: MK-1775 + olaparib

Location: United States

US States: CT, MA

US Contact: Multiple contacts: See www.clinicaltrials.gov for complete list of contacts.

NCT02042989

A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies

Cancer type: Unspecified Solid Tumor

Variant class: TP53 mutation

Other identifiers: 2013-0511, NCI-2014-01091, TrialTroveID-201319

Population segments: Line of therapy N/A, Stage III, Stage IV

Phase: I

Therapy: ixazomib + vorinostat

Location: United States

US State: TX

US Contact: Dr. Siqing Fu [713-563-1930]

ONC17-:www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

TP53 p.(V157F) c.469G>T (continued)**NCT02610075**

A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Cancer type: Unspecified Solid Tumor

Variant class: TP53 mutation

Other identifiers: D6015C00003, REFMAL 398, TrialTroveID-268385

Population segments: Liver mets, Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Phase: I

Therapy: MK-1775

Location: United States

US States: CO, TN

US Contact: AstraZeneca Clinical Study Information Center [877-240-9479; information.center@astrazeneca.com]

NCT02354547

A Phase I Study of SGT-53, a TfRscFv-Liposome-p53 Complex, in Children with Refractory or Recurrent Solid Tumors

Cancer type: Unspecified Solid Tumor

Variant class: TP53 mutation

Other identifiers: 1405-1316, SGT53-01-2, TrialTroveID-251586

Population segments: (N/A), Second line or greater/Refractory/Relapsed

Phase: I

Therapies: SGT-53, SGT-53 + chemotherapy

Location: United States

US State: TX

US Contact: Multiple contacts: See www.clinicaltrials.gov for complete list of contacts.

FBXW7 p.(R441W) c.1321C>T**NCT02873975**

A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency

Cancer type: Unspecified Solid Tumor

Variant class: FBXW7 mutation

Other identifiers: 16-281, TrialTroveID-284902

Population segments: Second line or greater/Refractory/Relapsed, Stage III, Stage IV

Phase: II

Therapy: prexasertib

Location: United States

US State: MA

US Contact: Dr. Geoffrey Shapiro [617-632-4942; Geoffrey_Shapiro@dfci.harvard.edu]

ONC17-:www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

FBXW7 p.(R441W) c.1321C>T (continued)**NCT01037790**

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Cancer type: Unspecified Solid Tumor**Variant class:** G1/S cell cycle pathway**Other identifiers:** NCI-2009-01467, Study 1006, TrialTroveID-120590, UPCC 03909, UPCC03909**Population segments:** Estrogen receptor positive, HER2 negative, HER2 positive, Metastatic, Progesterone receptor positive, Second line or greater/Refractory/Relapsed, Stage III, Stage IV, Triple receptor negative**Phase:** II**Therapy:** palbociclib**Location:** United States**US State:** PA**US Contact:** Peter O'Dwyer [855-216-0098; PennCancerTrials@emergingmed.com]**ONC17-:**www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Appendix: Evidence Summary by Variant Class

A variant class hierarchy was created to summarize gene variants with associated clinical evidence. Evidence items refers to citations across the different global data sources.

PTEN p.(V166fs) c.497_513delTAACTATTCCCAGTCAG

| Variant Class | Evidence Items |
|-----------------------|----------------|
| PI3K/AKT/MTOR pathway | 6 |
| ↳ PTEN aberration | 1 |
| ↳ PTEN mutation | 4 |

TP53 p.(V157F) c.469G>T

| Variant Class | Evidence Items |
|---------------|----------------|
| TP53 mutation | 8 |

FBXW7 p.(R441W) c.1321C>T

| Variant Class | Evidence Items |
|-------------------------|----------------|
| G1/S cell cycle pathway | 1 |
| ↳ FBXW7 mutation | 1 |

ONC17-:

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Appendix: Variant Details

DNA Sequence Variants

| Gene | Amino Acid Change | Coding | Variant ID | Locus | Allele Frequency Transcript | Variant Effect |
|-------|-------------------|----------------------------------|------------|----------------|-----------------------------|------------------------|
| FBXW7 | p.(R441W) | c.1321C>T | . | chr4:153249457 | 13.16% NM_033632.3 | missense |
| PTEN | p.(V166fs) | c.497_513delTAACT ATTCCAGTCAG | . | chr10:89711876 | 23.57% NM_000314.4 | frameshift Deletion |
| TP53 | p.(V157F) | c.469G>T | COSM10670 | chr17:7578461 | 15.30% NM_000546.5 | missense |

ONC17-:

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Terms and Conditions

The following paragraph on Liability is an extract from the Oncologica Tests' Terms and Conditions. The extract is to draw your attention to particular terms applicable to you but nothing set out here is intended to supersede or override our Terms and Conditions, which can be found on our website at www.oncologica.com under the title Oncologica Tests' Terms and Conditions. Please read these Oncologica Test Terms and Conditions carefully before you submit an order for the Oncologica Tests, as you will be bound by these Terms and Conditions, once a contract comes into existence as per paragraph 2 of the Oncologica Test's Terms and Conditions.

6. Liability

6.1 Oncologica operates in compliance with international ISO15189:2012 standards and is regulated by UKAS. The Oncologica Tests have not been cleared or approved by the United States Food and Drug Administration; however, such clearance or approval is not required.

6.2 The Patient agrees that the Oncologica Test Report is intended for clinical use and interpretation by a physician who is experienced and skilled in the use and interpretation of clinical test data. The Oncologica Test Report is based on the Sample submitted by the Patient. The Oncologica Test Report should not be considered or its contents applied to any other patient or any other sample. Oncologica does not update an Oncologica Test Report once it has been sent.

6.3 Information compiled in the Oncologica Test Report includes is from publicly available as well as proprietary sources. By updating the source database, Oncologica makes every effort to provide the most accurate and up-to-date information. However, Oncologica does not warrant or represent that the information in the Oncologica Test Report is accurate, timely or complete.

6.4 The Oncologica Test Report contains drug and clinical trial information. However, Oncologica does not warrant or represent that any drug or clinical trial identified by the Oncologica Test will guarantee a therapeutic response for a particular Patient. The drugs listed in an Oncologica Test Report are ranked on clinical evidence as to the predicted efficacy or appropriateness for the Patient. The Patient shall ensure that its physician shall evaluate and interpret the Oncologica Test Report, along with all other available clinical information about the Patient, to determine the best treatment decisions in their own independent medical judgment. Patient management decisions should not be based on a single test, nor solely on the information contained in the Oncologica Test Report.

6.5 Subject to paragraph 6.10, Oncologica shall have no liability for any use made of the information provided in the Oncologica Test Report, including but not limited to any report prepared by Oncologica summarising the results of the Oncologica Tests, any advice supplied by Oncologica, any decisions taken, or for any costs incurred by Patient and/or the Patient's physician and/or the Agent in consequence of such use, advice or decisions. The Oncologica Test and/or the Oncologica Test Report is not a substitute for the Patient's physician's professional judgment. The use of the information provided in the Oncologica Test Report is provided as a tool for the ordering physician's use in determining the appropriate treatment for the Patient. The decision as to what course of treatment and the appropriate use of the information provided by the Oncologica Test Report is solely that of the Patient's physician.

6.6 Oncologica does not warrant or represent or guarantee that the Oncologica Tests will identify an actionable genetic alteration that is linked to anti-cancer targeted therapies. Although the Oncologica Tests are comprehensive, in a proportion of Patients, the Oncologica Test result may not identify any actionable mutations for a patient's cancer. In the event that no actionable alteration in the Sample is identified by the Oncologica Test, then the Patient is still under full obligation to pay the Charges and no refund is available to the Patient and/or Agent.

6.7 The Oncologica Test identifies genomic actionable alterations found in the submitted Sample that are linked to anti-cancer targeted agents. Also note that this test only examines tumour, and not normal tissue from the patient, and therefore cannot distinguish between somatic and germline (i.e., heritable) alterations.

6.8 Subject to Clause 6.8, Oncologica shall not be liable to the Patient whether in contract, tort (including negligence and breach of statutory duty), or otherwise for any:

- (a) Error or defect in the Oncologica Test Report as a result of any inaccurate or incomplete information supplied by the Patient;
- (b) Loss of data or materials, including the Sample and/or the Report and including any loss arising as a result of the acts or omissions of a courier;
- (c) Indirect or consequential loss arising whether or not advised of the possibility of the same.

ONC17-:

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

6.9 Subject to the provisions of this Clause 6, Oncologica's total liability to the Patient in respect of all losses arising under or in connection with the Contract, whether in contract, tort (including negligence and breach of statutory duty), or otherwise, shall in no circumstances exceed the Charges paid for the Test that is the subject of the claim.

6.10 Nothing in the Contract limits or excludes the liability of Oncologica for breach of its obligations under section 12 of the Sale of Goods Act 1979 and/or section 2 of the Supply of Goods and Services Act 1982; death or personal injury resulting from negligence; or fraud or fraudulent misrepresentation.

6.11 If the Patient is a consumer (and not a business), the Patient expressly acknowledges and agrees that the Test is supplied to the Patient's specification and therefore there is no right to cancel the Test following acceptance under Clause 2.2. If the Patient is a consumer, then notwithstanding any other provisions of the Contract, none of the Patient's consumer statutory rights are affected.

ONC17-:

www.oncologica.com

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.
